cresco labs - CRLBF

CRLBF

Close Chg Chg %
0.82 0.05 6.66%

Closed Market

0.87

+0.05 (6.66%)

Volume: 820.05K

Last Updated:

Dec 4, 2025, 3:59 PM EDT

Company Overview: cresco labs - CRLBF

CRLBF Key Data

Open

$0.82

Day Range

0.76 - 0.88

52 Week Range

0.43 - 1.62

Market Cap

$293.25M

Shares Outstanding

357.62M

Public Float

334.66M

Beta

1.12

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.15

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.05M

 

CRLBF Performance

1 Week
 
13.78%
 
1 Month
 
-18.69%
 
3 Months
 
-27.50%
 
1 Year
 
-19.11%
 
5 Years
 
-91.91%
 

CRLBF Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 9
Full Ratings ➔

About cresco labs - CRLBF

Cresco Labs Inc. engages in cultivating medical grade cannabis, manufacturing medical products derived from cannabis cultivation, and distributing such products to medical or adult use consumers. It focuses on regulatory compliance while working to develop condition-specific strains of cannabis and non-invasive delivery methods. The company was founded by Charles Bachtel, Joseph Caltabiano, Dominic Sergi, Rob Sampson, and Brian McCormack on July 6, 1990 and is headquartered in Chicago, IL.

CRLBF At a Glance

Cresco Labs, Inc.
400 West Erie Street
Chicago, Illinois 60654
Phone 1-312-929-0993 Revenue 724.34M
Industry Agricultural Commodities/Milling Net Income -74,438,000.00
Sector Process Industries Employees 2,900
Fiscal Year-end 12 / 2025
View SEC Filings

CRLBF Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.438
Price to Book Ratio 0.675
Price to Cash Flow Ratio 2.39
Enterprise Value to EBITDA 4.133
Enterprise Value to Sales 1.006
Total Debt to Enterprise Value 0.877

CRLBF Efficiency

Revenue/Employee 249,773.448
Income Per Employee -25,668.276
Receivables Turnover 13.901
Total Asset Turnover 0.534

CRLBF Liquidity

Current Ratio 3.119
Quick Ratio 2.236
Cash Ratio 1.495

CRLBF Profitability

Gross Margin 47.31
Operating Margin 15.243
Pretax Margin -1.466
Net Margin -10.277
Return on Assets -5.486
Return on Equity -15.183
Return on Total Capital -6.679
Return on Invested Capital -6.593

CRLBF Capital Structure

Total Debt to Total Equity 134.703
Total Debt to Total Capital 57.393
Total Debt to Total Assets 47.194
Long-Term Debt to Equity 129.742
Long-Term Debt to Total Capital 55.279
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Cresco Labs - CRLBF

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
821.68M 842.68M 770.89M 724.34M
Sales Growth
+72.53% +2.56% -8.52% -6.04%
Cost of Goods Sold (COGS) incl D&A
436.94M 456.30M 433.06M 381.66M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
44.95M 57.73M 69.30M 65.99M
Depreciation
32.61M 47.37M 62.26M 58.89M
Amortization of Intangibles
12.34M 10.36M 7.05M 7.11M
COGS Growth
-13.78% +4.43% -5.09% -11.87%
Gross Income
384.75M 386.38M 337.83M 342.68M
Gross Income Growth
+1,359.81% +0.42% -12.57% +1.44%
Gross Profit Margin
+46.82% +45.85% +43.82% +47.31%
2021 2022 2023 2024 5-year trend
SG&A Expense
280.21M 309.86M 259.81M 223.69M
Research & Development
- - - -
-
Other SG&A
280.21M 309.86M 259.81M 223.69M
SGA Growth
+45.95% +10.58% -16.15% -13.90%
Other Operating Expense
16.00M 17.75M 14.83M 8.59M
Unusual Expense
314.35M 139.20M 150.16M 2.39M
EBIT after Unusual Expense
(225.80M) (80.44M) (86.97M) 108.02M
Non Operating Income/Expense
22.42M 12.05M 3.31M (59.74M)
Non-Operating Interest Income
938.00K 679.00K 2.42M 2.92M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
52.15M 58.52M 63.24M 58.90M
Interest Expense Growth
+27.48% +12.21% +8.08% -6.87%
Gross Interest Expense
52.15M 58.52M 63.24M 58.90M
Interest Capitalized
- - - -
-
Pretax Income
(255.53M) (126.91M) (146.90M) (10.62M)
Pretax Income Growth
-3,164.29% +50.34% -15.76% +92.77%
Pretax Margin
-31.10% -15.06% -19.06% -1.47%
Income Tax
40.11M 88.94M 32.95M 49.87M
Income Tax - Current - Domestic
77.84M 105.94M 46.19M 49.86M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
(43.49M) (18.19M) (41.99M) (997.00K)
Income Tax - Deferred - Foreign
5.76M 1.19M 28.75M 1.01M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(296.83M) (215.84M) (179.85M) (60.49M)
Minority Interest Expense
22.76M (3.80M) (4.33M) 13.95M
Net Income
(319.60M) (212.05M) (175.52M) (74.44M)
Net Income Growth
-290.11% +33.65% +17.22% +57.59%
Net Margin Growth
-38.90% -25.16% -22.77% -10.28%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(319.60M) (212.05M) (175.52M) (74.44M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(319.60M) (212.05M) (175.52M) (74.44M)
EPS (Basic)
-1.2183 -0.7112 -0.542 -0.2155
EPS (Basic) Growth
-212.95% +41.62% +23.79% +60.24%
Basic Shares Outstanding
262.33M 298.16M 323.82M 345.47M
EPS (Diluted)
-1.2183 -0.7112 -0.542 -0.2155
EPS (Diluted) Growth
-212.95% +41.62% +23.79% +60.24%
Diluted Shares Outstanding
262.33M 298.16M 323.82M 345.47M
EBITDA
133.49M 116.49M 132.50M 176.41M
EBITDA Growth
+168.32% -12.74% +13.74% +33.14%
EBITDA Margin
+16.25% +13.82% +17.19% +24.35%

Snapshot

Average Recommendation BUY Average Target Price 1.67
Number of Ratings 9 Current Quarters Estimate -0.018
FY Report Date 12 / 2025 Current Year's Estimate -0.148
Last Quarter’s Earnings -0.05 Median PE on CY Estimate N/A
Year Ago Earnings -0.177 Next Fiscal Year Estimate -0.074
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 5 3 8 8
Mean Estimate -0.02 -0.02 -0.15 -0.07
High Estimates 0.01 0.01 -0.12 0.06
Low Estimate -0.03 -0.03 -0.19 -0.13
Coefficient of Variance -91.37 -141.65 -18.34 -80.08

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 8 7 7
OVERWEIGHT 1 1 1
HOLD 0 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Cresco Labs in the News